IGF-1 LR3
Long R3 IGF-1 / Insulin-like Growth Factor 1 Long R3
IGF-1 LR3 is a lab-made IGF-1 analog with arginine at position 3 and a 13-amino-acid N-terminal extension, changes that cut binding to IGF-binding proteins and raise potency in cell studies. No human clinical trials have been published, so human dosing and safety are unknown; low blood sugar is a serious risk.
Half-life
Not established in humans
Typical Dose
20–80 mcg/day
48/80Route
subcutaneous
Category
growth_hormone
Evidence Overview
Strength of evidence across clinical, expert, and experimental lanes.
How IGF-1 LR3 is dosed in practice
Usually taken by subcutaneous (SubQ) injection. Typical range: 20–80 mcg/day. Half-life: Not established in humans. Each card gives the dose, frequency and duration from one evidence lane: Clinical (human trials), Expert (practitioner protocols) or Experimental (early or animal data). These ranges describe what has been studied or used; they are not a prescription.
Work out the units to draw with the reconstitution calculator, how long a vial lasts with the vial duration calculator, and how levels fall between doses with the half-life calculator.
Used in advanced bodybuilding circles. Users report muscle fullness, vascularity and strength gains. Hypoglycemia is a real and dangerous risk — must eat carbohydrates around injection time. Often run at 40–60 mcg/day for 4 weeks. Some users worry about gut and organ growth at high or chronic doses; this is unstudied.
- Bodybuilding community reports
- Community self-reports
Unlock Full Evidence Sources
Get complete clinical data, expert protocols, and experimental research for IGF-1 LR3 and 90+ other compounds with Pro.
Upgrade to ProInteraction Network
Known interactions with other compounds. Click nodes to explore connections.
Safety & Contraindications
- Cancer or history of cancer (potent growth factor)
- Diabetes or insulin resistance (hypoglycemia risk)
- Cardiac hypertrophy or organ enlargement concerns
- Pregnancy or breastfeeding
IGF-1 LR3: common questions
What is IGF-1 LR3?
IGF-1 LR3 is a lab-made IGF-1 analog with arginine at position 3 and a 13-amino-acid N-terminal extension, changes that cut binding to IGF-binding proteins and raise potency in cell studies. No human clinical trials have been published, so human dosing and safety are unknown; low blood sugar is a serious risk.
How is IGF-1 LR3 dosed?
IGF-1 LR3 is usually taken by subcutaneous (SubQ) injection. Typical range in DoseCraft's library: 20–80 mcg/day. Experimental (early or animal data): 40–80 mcg daily, post-workout preferred; Once daily on training days, half dose on rest days; 4 weeks on, 4 weeks off. These ranges describe what has been studied or used; they are not a prescription.
Is IGF-1 LR3 FDA-approved?
No. IGF-1 LR3 is not approved by the FDA for any use in people.
What is the half-life of IGF-1 LR3?
DoseCraft's library lists a half-life of Not established in humans. Half-life sets how often a compound is dosed and how long it takes to clear: about five half-lives.
Who should not use IGF-1 LR3?
Listed contraindications: Cancer or history of cancer (potent growth factor); Diabetes or insulin resistance (hypoglycemia risk); Cardiac hypertrophy or organ enlargement concerns; Pregnancy or breastfeeding.
Information is for educational purposes only. Always consult a licensed healthcare provider before starting any peptide regimen.
Page updated . How we grade evidence: methodology.